Is GSK a Strong Buy Right Now?
Dividend-paying pharmaceutical stocks have an outstanding track record of producing market-beating returns on capital. The core reason is that major drug manufacturers tend to generate enormous free cash flows, leading to exceptionally rich Dividend programs. Keeping with this theme, big pharma stocks sport a handsome 3.08% average Dividend yield, which compares rather favorably to the 1.56% average yield among S 500 stocks.
Not all dividend-paying pharma stocks are market slayers, however. Over the past 10 years, British pharma giant GSK (NYSE: GSK) has dramatically underperformed most of its big pharma peers as well as the broader markets. The good news is that GSK's outlook has brightened significantly since the carve-out of its consumer healthcare unit Haleon last year.
Source Fool.com
GSK plc ADR Aktie
Leichte Kaufneigung bei GSK plc ADR, mit mehr Buy- als Sell-Einschätzungen.
Eine Steigerung von über 20% ist für GSK plc ADR möglich, angesichts eines Kursziels von 49 € gegenüber 40.0 €.
